Although BRAFi/MEKi combination treatments produce impressive initial clinical responses in a subset of BRAF-mutant advanced melanoma patients, resistance to treatment rapidly emerges within a few months, rendering the therapy ineffective [6,7]. The gene discussed is BRAF; the disease is melanoma.